From Virtual Visits to Continuous Care: How Telehealth and Remote Patient Monitoring Are Reshaping the Healthcare Economy

For much of the past decade, telehealth was treated as a convenience layer—an efficient substitute for routine in-person visits that reduced travel time and scheduling friction. That framing has become obsolete. Nexvora Intelligence's latest research positions the global telehealth and remote patient monitoring (RPM) market as something far more structurally significant: a fundamental reorganization of how care is delivered, monitored, and paid for. The market's current scale—estimated at $170 billion to $205 billion globally in 2025—reflects not just the acceleration triggered by recent public health disruptions, but a durable shift in provider strategy, payer policy, and patient expectation.

The more consequential story is what happens next. Nexvora's modeled projections place the market at $430 billion to $560 billion by 2032, implying a compound annual growth rate of approximately 14% to 18%. That range is not simply a reflection of incremental adoption. It captures a structural pivot: health systems, payers, and employers are reallocating procurement budgets away from episode-based platforms and toward continuous-care infrastructure that generates measurable clinical and economic outcomes. Business leaders evaluating this market should understand that they are not observing a technology adoption curve—they are watching a redefinition of where and how healthcare value is created.

Within the broader telehealth category, remote patient monitoring is emerging as the highest-velocity segment. Nexvora's assessment places RPM's modeled annual growth rate in the high-teens to low-twenties percentage range through 2032—meaningfully above the growth trajectory of core teleconsultation services. This divergence is not accidental. RPM addresses a structural gap that virtual visits alone cannot close: the clinical blind spot between appointments, during which a patient's condition can deteriorate without clinical awareness. For patients managing chronic conditions such as heart failure, diabetes, hypertension, or COPD, that blind spot can translate directly into avoidable hospitalizations, emergency department visits, and declining quality of life.

Three converging drivers are fueling RPM's outperformance. First, chronic disease prevalence is rising globally, creating a large and expanding population for whom continuous monitoring delivers demonstrable value. Second, hospital-at-home programs—which allow patients recovering from acute episodes to be monitored in their own residences—are scaling rapidly in mature healthcare markets, creating institutional demand for connected device ecosystems and clinical oversight platforms. Third, post-discharge monitoring programs have become a priority for health systems operating under value-based contracts, where readmission rates directly affect reimbursement. Implication: investors and strategists who treat RPM as a subset of telehealth are likely underestimating its independent strategic weight.

The device layer underpinning RPM is evolving in parallel. Connectivity-enabled blood pressure cuffs, cardiac monitors, continuous glucose sensors, pulse oximeters, and weight scales are becoming more clinically accurate, more consumer-friendly, and more tightly integrated with the software platforms that translate raw biometric data into actionable clinical alerts. The hardware-software integration challenge remains real, but the market is increasingly rewarding vendors who solve it elegantly rather than leaving the integration burden to provider IT departments.

North America accounts for an estimated 42% to 48% of 2025 global telehealth and RPM spending, according to Nexvora's modeled regional breakdown. The United States is the primary driver, where a combination of payer reimbursement frameworks, employer healthcare purchasing, and enterprise platform adoption among integrated health systems has created favorable conditions for scaled deployment. Critically, the reimbursement environment—though still variable across payers and program types—has matured enough to provide investment confidence for platform vendors and provider organizations alike. Canada's market is smaller but directionally aligned, with provincial health authorities experimenting with virtual-first care models in both urban and rural contexts.

Asia-Pacific presents a different and in some respects more dynamic growth story. Nexvora's assessment identifies it as the fastest-growing region through the forecast period, driven by a convergence of factors that are structurally distinct from those shaping Western markets. Large urban-rural access gaps in markets such as India, Indonesia, and the Philippines create acute demand for remote consultation and monitoring capabilities that can extend specialist reach without requiring physical infrastructure. Mobile-first healthcare ecosystems in markets including China, South Korea, and Southeast Asia are enabling rapid adoption of app-based health management platforms. Meanwhile, the rising burden of cardiometabolic disease across the region is creating clinical urgency around chronic disease management programs that benefit directly from RPM capabilities. The combination of scale, unmet need, and digital infrastructure investment makes Asia-Pacific the region to watch for growth-stage market participants.

Europe occupies a middle position—advanced enough in digital health infrastructure to support sophisticated deployments, but constrained by regulatory fragmentation across member states and reimbursement heterogeneity that slows enterprise-scale rollouts. The United Kingdom's NHS-led digital health initiatives and Germany's Digital Healthcare Act represent meaningful policy frameworks that are beginning to unlock structured procurement. Latin America and the Middle East are earlier-stage but represent meaningful long-term opportunities as smartphone penetration, private health insurance expansion, and government digitization programs mature.

One of the clearest strategic signals emerging from Nexvora's competitive landscape analysis is the accelerating consolidation of the market around integrated platforms rather than specialized point solutions. In the market's earlier phase, health systems frequently procured separate tools for video visits, patient engagement, remote monitoring, care management, and analytics—often from different vendors, with limited interoperability. That model is under visible pressure. Provider organizations are experiencing significant friction from fragmented data flows, disconnected clinical workflows, and the administrative burden of managing multiple vendor relationships.

The procurement criteria shift is decisive. Health system technology leaders are increasingly evaluating telehealth and RPM vendors on their ability to deliver a unified capability stack: virtual care, connected device management, patient engagement and adherence tools, clinical escalation protocols, population-level analytics, and deep electronic health record integration. Vendors who can credibly demonstrate performance across all of these dimensions—and who can show measurable outcomes data to support procurement decisions—hold a significant advantage over specialists who excel in one functional area. Nexvora's assessment suggests that the competitive landscape will continue to consolidate around a smaller number of scaled platform providers over the next three to five years, with point solutions either acquiring adjacencies, being acquired, or ceding enterprise accounts to more integrated competitors.

This consolidation dynamic has significant implications for health system strategy as well as for market participants. Provider organizations that have invested in point-solution portfolios face a strategic decision about whether to rationalize their vendor landscape proactively or manage the integration complexity themselves. Those that move toward platform consolidation earlier are likely to realize greater workflow efficiency and data coherence—both of which translate into stronger clinical and operational outcomes, which in turn strengthen the business case for continued telehealth and RPM investment.

Perhaps the most operationally significant finding in Nexvora's research concerns the evolution of how provider organizations justify and evaluate telehealth and RPM investments. Visit volume—the number of virtual encounters enabled—was the dominant procurement metric in the market's early phase. It was easy to measure, easy to report, and easy to use as a proxy for utilization. That metric is being supplemented—and in some cases replaced—by outcomes-oriented performance indicators that reflect healthcare's broader shift toward value-based accountability.

The outcomes that procurement committees are now tracking include reduced hospital readmission rates, improved medication adherence, lower rates of avoidable emergency department utilization, improved patient access to specialist consultations, and clinician workflow efficiency. The last of these is particularly significant. Clinician burnout is a recognized systemic challenge in healthcare, and technology platforms that add to administrative burden rather than reducing it face real adoption resistance at the point of care. Vendors who can demonstrate that their platforms reduce clinician cognitive load—through intelligent alert prioritization, streamlined documentation, and workflow integration—are differentiating on a dimension that procurement committees increasingly weight heavily.

Nexvora's assessment is that the outcomes imperative will intensify over the forecast period as value-based care contract penetration increases in North America and as similar frameworks gain traction in Europe and parts of Asia-Pacific. For vendors, this creates both an obligation and an opportunity: those who invest in outcomes data infrastructure, clinical evidence generation, and transparent reporting will be positioned to win and retain enterprise accounts in a procurement environment that increasingly demands proof over promise.

No honest analysis of the telehealth and RPM market would be complete without an equally candid assessment of the constraints that limit its growth trajectory. Nexvora's research identifies reimbursement variability as the most pervasive near-term constraint in mature markets. While core telehealth reimbursement has been established by major public and private payers in the United States, coverage for RPM services—particularly the device management, data review, and care management components—remains inconsistent across payer types, plan designs, and patient populations. This variability creates financial risk for provider organizations considering large-scale RPM program deployment and complicates the business case for smaller practices.

Connectivity and device access represent a constraint that is both technical and equity-relevant. Remote patient monitoring is most clinically valuable for populations with high chronic disease burden—a category that often overlaps substantially with lower-income, rural, and elderly populations that face uneven broadband access, limited smartphone ownership, or lower comfort with digital health tools. Solving the access problem is not purely a technology challenge; it requires thoughtful program design, patient support infrastructure, and in some cases hardware subsidization. Vendors and provider organizations that address this systematically—rather than defaulting to solutions optimized for digitally confident, well-resourced patients—will serve both a broader market and a more equitable healthcare mission.

Cybersecurity and data integrity obligations represent a third constraint category that Nexvora's analysis treats as increasingly market-defining rather than peripheral. The combination of connected devices, cloud-based platforms, electronic health record integrations, and sensitive patient health data creates a complex attack surface. Regulatory expectations around data protection are rising in all major markets, and high-profile security incidents carry reputational as well as regulatory consequences. Vendors who treat security as a core product attribute—rather than a compliance checkbox—will be better positioned as health system procurement teams subject telehealth and RPM platforms to increasingly rigorous security evaluations.

For health system executives, the strategic priority that emerges from Nexvora's research is clarity about the transition from episodic to continuous care delivery. Organizations that have deployed telehealth primarily as a visit-volume tool should be actively evaluating whether their current platform investments can support the clinical complexity and data infrastructure requirements of comprehensive RPM programs. The health systems that will extract the greatest value from this market over the next seven years are those that approach telehealth and RPM as a care delivery model transformation—one that requires clinical workflow redesign, staff training, outcome measurement infrastructure, and patient engagement strategy in addition to technology procurement.

For investors and platform vendors, Nexvora's modeled growth trajectory signals substantial opportunity, but the nature of the opportunity is shifting. Platforms that compete on feature breadth, integration depth, and outcomes evidence are better positioned than those competing primarily on price or single-function capability. The consolidation dynamic suggests that the market will reward scale—both in terms of data assets that can support outcomes reporting and in terms of the platform comprehensiveness that enterprise procurement committees increasingly require. Strategic acquisitions of specialized capabilities—particularly in analytics, patient engagement, and device management—are likely to accelerate as larger platform providers seek to close functional gaps.

For policymakers and payers, the research underscores the leverage that reimbursement policy holds over market development. Consistent, durable reimbursement frameworks for RPM services—particularly those covering care management and clinical oversight activities rather than device costs alone—would substantially reduce the financial risk that currently constrains provider organization investment. The evidence base supporting RPM's clinical and economic value is strengthening; translating that evidence into stable reimbursement policy represents one of the highest-leverage interventions available to accelerate both market growth and population health outcomes.

The title of Nexvora's underlying report—from virtual visits to continuous care—captures something more than a product evolution. It describes a fundamental change in the relationship between patients and the healthcare system. The traditional model assumed that care happened during encounters: a scheduled appointment, an emergency visit, a procedure. Between those encounters, patients were largely on their own, managing their conditions with whatever knowledge, resources, and discipline they possessed. The telehealth and RPM market is building the infrastructure to change that assumption—to make clinical awareness and support available not just during encounters, but in the spaces between them.

Nexvora's assessment is that this shift will be one of the defining healthcare developments of the 2025–2032 period. It will not be uniform, smooth, or without friction. Reimbursement will remain uneven in some markets. Access gaps will persist for some populations. Platform consolidation will displace some vendors and disrupt some provider organization procurement plans. But the directional momentum is clear, the investment flows are substantial, and the clinical logic is compelling. Organizations that position themselves thoughtfully within this evolving landscape—with clear strategies, realistic assessments of constraints, and genuine commitment to outcomes accountability—are the ones Nexvora expects to define the continuous care economy.